Companies › Faeth Therapeutics
2 active drug programs in 11 registered trials: 6 Phase 1, 5 Phase 2; Oncology; next expected readout Sep 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sapanisertib Serine/threonine-protein kinase mTOR inhibitor | MTOR | Phase 2 | Endometrial Cancer; HR+ HER2- Breast Cancer; Locally Advanced Bladder Urothelial Carcinoma; Advanced Lymphoma … | Sep 2028 |
| Serabelisib PI3-kinase p110-alpha subunit inhibitor | PIK3CA | Phase 2 | Endometrial Cancer; HR+ HER2- Breast Cancer | Sep 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02142803 | Sapanisertib | Phase 1 | Adult Glioblastoma | Oncology | Dec 2020 |
| NCT03047213 | Sapanisertib | Phase 2 | Locally Advanced Bladder Urothelial Carcinoma | Oncology | Nov 2026 |
| NCT04250545 | Sapanisertib | Phase 1 | Leptomeningeal Neoplasm | Oncology | Nov 2026 |
| NCT06390865 | Sapanisertib | Phase 2 | Advanced Lymphoma | Oncology | Dec 2026 |
| NCT06385496 | Sapanisertib | Phase 2 | Advanced Lymphoma | Oncology | Dec 2026 |
| NCT02503722 | Sapanisertib | Phase 1 | Metastatic Lung Non-Small Cell Carcinoma | Oncology | Feb 2027 |
| NCT06811116 | Sapanisertib | Phase 1 | Advanced Hepatocellular Carcinoma | Oncology | Aug 2027 |
| NCT06463028 | Sapanisertib | Phase 2 | Endometrial Cancer | Oncology | Sep 2028 |
| NCT06463028 | Serabelisib | Phase 2 | Endometrial Cancer | Oncology | Sep 2028 |
| NCT07558733 | Sapanisertib | Phase 1 | HR+ HER2- Breast Cancer | Oncology | May 2029 |
| NCT07558733 | Serabelisib | Phase 1 | HR+ HER2- Breast Cancer | Oncology | May 2029 |
Cash and short-term investments of $175m on 2026-09-30; operating cash outflow about $53m a year; runway about 40 months at that burn, to Jan 2030; 4 of 4 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 10 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Eli Lilly Restorbio Celcuity iVascular S.L.U. Palvella Therapeutics Supernus Pharmaceuticals SAPU NANO (US) AstraZeneca Novartis Recursion Pharmaceuticals
C4 Therapeutics Black Diamond Therapeutics Kyntra Bio Celcuity Teligene US
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.